French drug maker Sanofi SA, pressing forward with a global realignment, Monday notified about three dozen research and development employees in Massachusetts that their jobs will be eliminated, according to employees.
The jobs are in labs supporting the biosurgery, bone and joint disease, drug delivery discovery, and biomaterial engineering groups that were formerly part of Genzyme Corp., the employees said. Those labs are in Cambridge, Framingham, and Waltham.
Sanofi paid $20.1 billion to acquire Cambridge-based Genzyme in 2011 and has renamed the division Sanofi Genzyme. In a global restructuring that began last summer, Sanofi shifted oversight for research and development jobs in Massachusetts and elsewhere to a corporate research organization based in Paris.
A spokeswoman said Monday that she couldn’t immediately comment on the cuts. Sanofi told its labor unions earlier this month that it is paring about 600 jobs in France. The company has not confirmed cuts at other locations.
By Robert Weisman
Source: Boston Globe
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
